Trochanteric Fractures
13
0
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.7%
1 terminated out of 13 trials
75.0%
-11.6% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (13)
ZNN Bactiguard Cephalomedullary Nails PMCF Study
Insignia™ Hip Stem Outcomes Study
G7 Freedom Constrained Vivacit-E Liners
G7 BiSpherical Acetabular Shell PMCF Study
G7 Dual Mobility With Vivacit-E or Longevity PMCF
Post-market Surveillance Study With the HYPERION Hip Endoprosthesis System in Defect Reconstruction
Treatment Of Unstable Trochanteric Fracture: A Comparative Study Between DHS And DHS With Trochanteric Stabilization Plate
PFNA vs Dual Mobility in Treatment of Unstable Trochanteric Fractures
Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation (PFNA)-Asia
Trochanteric Hip Fractures (AO A2) SHS With or Without Trochanteric Stabilizing Plate - Rct Using RSA
Results of Gamma Nail in Trochentric Fractures of the Adults
Interest of Navigation for the Treatment of Pertrochanteric Fractures With the Gamma 3 Nail
Effect of PTH(1-34) Treatment on Fracture Healing in Vivo